March 7-9, 2022 | Digital Event
WELCOME
www.ild-summit.com
Register &
Pay by Friday
January 14 &
Save $300
2nd Annual
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
SPEAKERS
Compare Fibrotic Versus Inflammatory ILDs to
Accelerate Target Identification
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
Define Progression in Progressive Fibrosis to Uncover
Predictive Biomarkers & Streamline Stratification
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
Nina Patel
Director of Clinical
Development &
Medical Affairs ILD
Boehringer
Ingelheim
Shannon Turley
Vice President Cancer Immunology
& Discovery
Genentech
Martin Kolb
Professor & Chief
Editor of European
Respiratory Journal
McMaster
University
Toby Maher
Director
Interstitial Lung,
Disease Program
USC
Shane Olwill
Senior Vice
President & Chief
Development
Officer
Pieris
Pharmaceuticals
+1 617 455 4188
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
Cara Williams
Vice President
& Head of
Preclinical Biology,
Inflammation
& Immunology
Research
Pfizer
PARTNER WITH US
28 Expert Speakers Including:
AGENDA
Navigate Clinical Drug Development to Understand
ILD Trial Design & Expand Your IPF Pipeline to
Broader Indications
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
Deepen Scientific Understanding of Inflammatory &
Fibrotic ILDs, Investigate Biomarkers to Stratify Trial
Populations and Identify Endpoints Which are Likely
to Predict Clinical Success in Your Next Clinical Trial
Built to identify and advance indication expansions of IPF pipeline into fibrotic
and inflammatory ILDs; with scientific insight from the hottest ILD and IPF
stakeholders in the space, the 2nd ILD Summit is uniquely positioned to translate
biological insights into therapeutic development opportunity across NSIPs, CT-ILDs,
Sarcoidosis, HP and more.
From exploring machine learning for more innovative ILD imaging, to analyzing
biologics, small molecules and antibodies to determine which one is most suited
to streamline inhaled drug delivery, this comprehensive forum will unite 100+ ILD
heavyweights to dissect and utilize pioneering scientific research to optimize their ILD
drug development strategy.
Acceleron Pharma
The meeting provides
a very thorough review of
the ILD landscape from
bench to bedside
Lassen Therapeutics
New learnings, confirmation
of previous postulates and
great opportunity to increase
my network
AbbVie
AGENDA
Join internationally renowned ILD, respiratory and fibrosis experts from Boehringer
Ingelheim, Pfizer, Genentech, Novartis and more at this unique industry focused
forum and leave with the expertise your team needs to optimize your ILD drug
development approach for 2022 and beyond.
The ILD summit was a
high quality event bringing
together leaders from
academia and industry sharing
the latest research and clinical
learnings in the field of fibrotic
pulmonary diseases.
SPEAKERS
With a clear path to approval set out for SSc-ILD opening opportunity to address
progressive fibrotic phenotypes and the remaining populations with inflammatory
drivers of ILD; the pulmonary fibrosis field is exploding with innovative attempts to
do better and bring transformative therapies to more patients.
Hear what previous
ILD Summit attendees
thought:
WELCOME
Welcome to the
2nd ILD Summit
Your Top 5 Takeaways From Key Stakeholders:
+1 617 455 4188
@
Discover how
pneumoproteitns
and cytokines can be
used to strategically
enrich SSc-ILD
clinical trials with
The University of
Texas and uncover
groundbreaking
research on imaging
based biomarkers,
CT Scans/data
collection with UCL
to understand how
it can be used to
predict FVC decline
info@hansonwade.com
www.ild-summit.com
Examine
inflammatory
interstitial lung
disease from a
drug development
perspective
with Pfizer to
comprehensively
understand the
disease signatures,
cellular pathways
and disease
mechanisms involved
in inflammatory ILD
development and
progression
Deep dive into the
lumping versus
splitting debate
in the context of
disease progression
with McMaster
University to hear
how to evolve
biomarkers in
applying splitting
strategies and
understand
the differences
between targeted
therapies and more
broadly antifibrotic
approaches
REGISTER YOUR PLACE
2
Investigate
emerging ILD
therapeutic
approaches with
Saje Pharma
and Pieris
Pharmaceuticals to
debate the merits of
single versus multiple
benefit drugs for ILD
and discover how
anticalins can be
utilized to optimize
treatment of lung
fibrosis
PARTNER WITH US
Uncover the
clinical research
propelling ILD
drug development
forwards in 2022
with Boehringer
Ingelheim and
Novartis to further
your understanding
of the inflammatory/
progressive fibrosing
ILD phenotype,
identify novel
outcomes and utilize
clinical data to
strategically inform
your clinical trial
design
Craig Conoscenti
Medical Expert ILD
Respiratory Clinical
Development &
Medical Affairs
Boehringer
Ingelheim
David Barber
Professor of
Machine Learning
UCL
Dinesh Khanna
Professor
University of
Michigan
Elizabeth Renzoni
Consultant
Respiratory
Physician, Honorary
Senior Lecturer
Imperial College
London
Eric White
Senior Clinical
Program Lead
Boehringer
Ingelheim
Farrell Simon
Vice President
& Head of US
Marketing
Trevi
Therapeutics
Glenn Rosen
Chief Scientific
Officer
Optikira &
Biomotiv
Jason Laufer
Chief Executive
Officer
Remedy Cell
Majd Mouded
Executive Director
Novartis
Margaret
Neighbors
Principle Scientist
Genentech
Martin Kolb
Professor
McMaster
University
Matt Bradley
Founder, Chairman,
President, & Chief
Technical Officer
SAJE Pharma
Nicolas Guisot
Research Fellow &
Project Leader
Redx Pharma
Nina Patel
Director – Clinical
Development &
Medical Affairs ILD
Boehringer
Ingelheim
Paolo Cameli
Pulmonologist
University of
Siena
+1 617 455 4188
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
Carsten Ehrhardt
Professor of
Pharmacy
Trinity College
Dublin
PARTNER WITH US
Cara Williams
Vice President
& Head of
Preclinical Biology:
Inflammation
& Immunology
Research Unit
Pfizer
AGENDA
Adam Byrne
Professor
Imperial College
London
SPEAKERS
3
March 7-9, 2022 | Digital
WELCOME
Your 25+ Expert Speakers
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
Rohit Batta
Chief Scientific
Officer
Vicore Pharma
Peter Fernandes
Vice President &
Chief Regulatory,
Quality & Safety
Officer
Bellerophon
Therapeutics
March 7-9, 2022 | Digital
Shane Olwill
Senior Vice
President & Chief
Development
Officer
Pieris
Pharmaceuticals
Simon Walsh
Consultant
Thoracic
Radiologist,
Machine Learning
Scientist & Imaging
Chair
Imperial College
London
Simona Spennato
Head of Nonobstructive Disease
Unit, Global Clinical
Development, R&D
Chiesi
Steve Jones
President
EUIPFF
Tejaswini Kulkarni
Director of
Interstitial Lung
Disease Program
University of
Alabama
Toby Maher
Director
Interstitial Lung,
Disease Program
USC
Vanessa Neins
Senior Scientist
- Biology Lead
Respiratory
Pieris
Pharmaceuticals
Lung Therapeutics
Synexus
4
+1 617 455 4188
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
Great event exceptional networking opportunities.
High quality of presentations. Very efficient way to
spend my time
PARTNER WITH US
Overall I thought very highly of the conference and the
job Hanson Wade did as an organizer. Great speakers, lots of
useful information, very timely. Top KOLs in the field
AGENDA
Shervin Assassi
Director of
the Division of
Rheumatology
The University of
Texas
SPEAKERS
Shannon Turley
Vice President
of Cancer
Immunology
Discovery
Genentech
WELCOME
Your 25+ Expert Speakers
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
9.00-4.30 EDT | 6.00 - 1.30 PDT
WELCOME
Pre-Conference Day
Monday, March 7
Our entire pre-conference discussions day morning is dedicated to analyzing and scrutinizing the latest
progress in inhaled drug delivery followed by a quick lunch break to refuel and network with fellow ILD drug
developers via our custom-built virtual event platform.
After lunch, you can continue diving deeper into inhaled drug delivery or choose to attend our dedicated
“Exploring Biomarkers for ILD Clinical Trials” afternoon workshop. The choice is yours! Take a look at our PreConference Day agenda at a glance to view the full format
SPEAKERS
Agenda at a Glance
Inhaled Drug Delivery Morning
Lunch & Networking
OR
Inhaled Drug Delivery Afternoon
Biomarkers for ILD Clinical Trials Workshop
9.00 | 6.00
Registration & Networking
10.00 | 7.00
Deep Diving into Delivery Mechanisms: Comparing &
Contrasting Inhaled vs Systemic Drug Delivery in the Context
of ILD Treatment
Carsten Ehrhardt
Professor of
Pharmacy
Trinity College
Dublin
11.00 | 8.00
• Evaluating the choice of treatment for ILD based on specific ILD
diagnosis, - including both systemically delivered agents and inhaled
delivered agents.
• Recently approved for ILD is an inhaled pulmonary arterial vasodilator
that is also available as systemic delivered doses to treat PAH.
• Discussing the pros and cons of inhaled vs. systemic administration agents
for ILD aimed at targeting the MOA, V/Q matching, ILD diagnosis and the
recent clinical experience on these delivery options to date
10.30 | 10.30
Considerations for Inhaled Drug Delivery
• Basic considerations for inhaled drug delivery
• Inhaled drug delivery challenges and how to overcome
• Inhaled drug delivery for ILD specifically
PARTNER WITH US
Peter Fernandes
Vice President & Chief
Regulatory, Quality &
Safety Officer
Bellerophon
Therapeutics
AGENDA
Investigating Inhaled Drug Delivery for Interstitial Lung Disease
Integrating Inhaled Therapeutics with ILD Mechanisms to Streamline Your Drug Delivery
• Panel Discussion and Q&A with Preceding Speakers:
11.30 | 8.30
5
+1 617 455 4188
@
Morning Break & Networking
info@hansonwade.com
www.ild-summit.com
Carsten Ehrhardt
Professor of Pharmacy
Trinity College Dublin
REGISTER YOUR PLACE
Peter Fernandes
Vice President & Chief Regulatory,
Quality & Safety Officer
Bellerophon Therapeutics
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
9.00-4.30 EDT | 6.00 - 1.30 PDT
12.00 | 9.00
Exploring the Patient Perspective on Inhaled Drug Delivery
• Reviewing the advantages and disadvantages from a
patient perspective
• How do patients perceive risks and benefits of inhaled drug delivery?
• Understanding the patient experience for inhaled drug delivery
Steve Jones
President
EUIPFF
Lunch & Networking
Investigating Inhaled Drug Delivery
for Interstitial Lung Disease Afternoon
OR
Exploring Biomarkers for
ILD Clinical Trials Afternoon
1.30 | 10.30 Audience Discussion: Utilizing Lessons
Learned from Inhaled Pirfenidone for IPF to
Strategize & Enhance Effective Inhaled Drug
Delivery for Interstitial Lung Disease
1.30 | 10.30 Utilizing Biomarkers to Identify Patient
Over the past few years, significant strides have been
made in the delivery of inhaled pirfenidone for IPF,
however this has not been without it’s fair share of
setbacks. What can the ILD drug development community
learn from this? Join this interactive audience discussion
to deep dive into the success, failures and challenges
of delivering inhaled pirfenidone to treat IPF and leave
with the knowledge you need to strategically inform and
optimize your inhaled drug delivery approach.
• Review the evolution of molecular and imaging
biomarkers in ILD
• Discuss an overview of application of these biomarkers
in personalizing ILD clinical trial designs and potentially,
shorten trial time
• Understand the challenges in clinic utility of these
molecular and imaging biomarkers
Tejaswini Kulkarni, Director of Interstitial Lung Disease
Program, University of Alabama
2.00 | 11.00 Moderated Discussion: Analyzing
Biologics, Small Molecules & Antibodies for the
Treatment of ILD to Determine Which One is Most
Easily Inhaled, Nebulized & Absorbed by the
Alveoli
2.00 | 11.00 Learning how to Use Biomarkers to
of Secretomes to Treat IPF & the Challenges of
Optimizing Inhaled Drug Delivery
• Lessons learned from SSc-ILD
• Molecularly profiling across multiple interstitial lung diseases
• Combining ILD biomarker knowledge and clinical utility where is the field at and where do we need to go next?
Margaret Neighbors, Principle Scientist, Genentech
2.30 | 11.30 Considerations for Clinical Trial
Biomarker Selection
• Panel Discussion and Q&A with Preceding Speakers:
Tejaswini Kulkarni, Director of Interstitial Lung Disease
Program, University of Alabama
Margaret Neighbors, Principle Scientist, Genentech
3.00 | 12.00 Afternoon Break & Networking
+1 617 455 4188
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
• Exploring the potential of Activated Remedy cell
Secretome (ARcS)
• Investigating the utility of the Secretome in murine
bleomycin models
• Analyzing the outcome of Secretome experiments in
PCLS explants from end stage IPF patients
Jason Laufer, Chief Executive Officer, Remedy Cell Ltd
Distinguish Patients with Fibrotic vs Inflammatory
ILD in Order to Strategically Stratify Trial
Populations & Maximize Trial Efficiency
PARTNER WITH US
2.30 | 11.30 Harnessing the Therapeutic Power
Populations Which are More Receptive to Your ILD
Therapeutic in Order to Design and Conduct Faster
Trials in a Shorter Time Frame
AGENDA
• Discussing and debating the benefits and drawbacks
of biologics, small molecules and antibodies for inhaled
drug delivery
• Understanding what characteristics give rise to more
easily inhaled molecules
• Exploring challenges associated with alveolar uptake
of inhaled therapies in interstitial lung disease and
understanding how to overcome them
Shane Olwill, Senior Vice President & Chief Development
Officer, Pieris Pharmaceuticals
Carsten Ehrhardt, Professor of Pharmacy, Trinity College
Dublin
SPEAKERS
12.30 | 9.30
6
WELCOME
Pre-Conference Day
Monday, March 7
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
9.00-4.30 EDT | 6.00 - 1.30 PDT
3.30 | 12.30 Advantages & Disadvantages of
Different Molecule Types for Inhaled Drug
Delivery
3.30 | 12.30 Audience Discussion: Systematically
Identifying & Validating New Biomarkers for
ILD: How to Select and Assess the Viability of
Novel Biomarkers for More Effective ILD Drug
Development
The difference between a successful and unsuccessful
clinical trial can come down to what biomarker you choose
to measure the efficacy of your therapeutic which is why
it’s critical to play close attention to how you incorporate
them into you clinical trial design and execution. Join
this structured audience discussion to debate how to
strategically select your next ILD biomarker with fellow ILD
experts and optimize your approach to tackling common
challenges associated with utilizing biomarkers in ILD
clinical trials.
4.00 | 1.00 Practical Experience of Delivering
4.00 | 1.00 Enrichment Strategies on SSc-ILD
• Considerations when developing inhaled drugs for
fibrotic ILD
• Discussing experience from the topical IPF study
• Assessing effectiveness of inhaled drug delivery
Toby Maher, Director, Interstitial Lung, Disease
Program USC
• Impact of Background Treatment on SSc-ILD Trial Design
• Role of pneumoproteitns for enrichment
• Role of inflammatory cytokines for enrichment
Shervin Assassi, Director of the Division of Rheumatology,
The University of Texas
Inhaled Drugs in Fibrotic Lung Disease
Clinical Trials
PureTech Health
Tremendous program with excellent synergies across
the disciplines... basic biology, preclinical science, and
clinical directions for idiopathic pulmonary fibrosis
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
OptiKira
PARTNER WITH US
Great virtual summit with interesting speakers and
a well-planned out digital platform
AGENDA
4.30 | 1.30 End of Day
+1 617 455 4188
SPEAKERS
• Panel Discussion and Q&A with Preceding Speakers:
Shane Olwill, Senior Vice President & Chief Development
Officer, Pieris Pharmaceuticals
Carsten Ehrhardt, Professor of Pharmacy, Trinity College
Dublin
Jason Laufer, Chief Executive Officer, Remedy Cell Ltd
7
WELCOME
Pre-Conference Day
Monday, March 7
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
8.30 - 5.00 EDT | 5.30 - 2.00 PDT
WELCOME
Conference Day One
Tuesday, March 8
Examining Inflammatory Interstitial Lung Disease from a Drug Development Perspective
8.25 | 5.25
Chair’s Opening Remarks
8.30 | 5.30
Registration & Networking
Comparing & Contrasting Fibrotic & Inflammatory ILDs in
Order to Comprehensively Understand Key Differences in Their
Development & Progression & Learning How This Influences
Drug Development
9.00 | 6.00
• Identifying disease signatures and key cellular players in fibrosis
associated with ILDs
• Examining Autoimmune versus Idiopathic progressive lung fibrosis
• Assessing pan fibrotic mechanisms versus disease specific mechanisms –
how best to treat pulmonary fibrosis
9.30 | 6.30
Nina Patel
Director – Clinical
Development &
Medical Affairs ILD
Boehringer
Ingelheim
Understanding How to Define Patient Populations, Select
Optimal Intervention Points & Outline Clear Therapeutic
Outcomes to Streamline the Design & Development of
Therapies for Inflammatory ILDs
• Utilizing clinical parameters versus radiographic parameters to define
patient subgroups
• Clinical versus physiologic versus radiologic parameters to determine
timing of intervention
• Choosing clinical trial outcomes in a heterogeneous trial population
Dinesh Khanna
Professor
University of
Michigan
Designing Trials for Inflammatory ILDs in 2022 & Beyond:
Spotlight on Ssc-ILD
• Revealing lessons learned from recent scleroderma ILD clinical trials
• Discussing trial design in at-risk population for ILD versus those with
clinical or established ILDs
• Understanding what factors you must consider to optimize success of
your therapeutic during clinical trials
10.30 | 7.30
Overview of Respiratory clinical and pre-clinical pipeline
11.00 | 8.00
Morning Break & Speed Networking
Biomarkers 101: Exploring the Emerging Consensus on
Which Biomarker is the Most Useful for ILD Drug Development
12.00 | 9.00
David Barber
Professor of Machine
Learning
UCL
• Using a database to streamline IPF/ILD imaging
• Using CT Scans to predict mortality
• Encouraging data sharing to optimize effort to find useful CT based
biomarkers
Paolo Cameli
Pulmonologist
University of Siena
Exploring Biomarkers for Differential Diagnosis of Interstitial
Lung Diseases
• Investigating the potential of biomarkers for ILD diagnosis
• Analyzing multiple types of biomarkers for ILD diagnosis
• Discussing advantages and disadvantages of biomarkers for ILD
diagnosis
1.00 | 10.00
@
Lunch & Networking
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
12.30 | 9.30
+1 617 455 4188
OSIC Project – Exploring Imaging Based Biomarkers, CT Scans/
Data Collection to Predict FVC Decline
PARTNER WITH US
• Exploring Chiesi’s mission as Research Group and key elements in several
respiratory diseases
• Overview of Respiratory clinical and pre-clinical pipeline, with a focus on
IPF research commitment
• Investigating pre-clinical imaging approaches translatable to the
clinical setting (e.g. microCT, microPET) withsharing of examples from
our internal research
Simona Spennato
Head of Nonobstructive Disease
Unit, Global Clinical
Development, R&D
Chiesi
AGENDA
10.00 | 7.00
8
SPEAKERS
Cara Williams
Vice President
& Head of
Preclinical Biology:
Inflammation
& Immunology
Research Unit
Pfizer
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
8.30 - 5.00 EDT | 5.30 - 2.00 PDT
WELCOME
Conference Day One
Tuesday, March 8
Revealing Supportive Care & Symptom Management for ILD Treatment
1.30 | 10.30
Farrell Simon
Vice President
and Head of US
Marketing
Trevi
Therapeutics
Exploring the Impact & Importance of Quality of Life on the
Patient Journey
• What is the importance of inclusion of QoL measures in ILD trials?
• How to choose meaningful QoL measures?
• What are the linkages between QoL measures and impact on
reimbursement?
2.00 | 11.00
Peter Fernandes
Vice President &
Chief Regulatory,
Quality & Safety
Officer
Bellerophon
Therapeutics
• Robust clinical endpoints should be able to measure a clinically meaningful
improvement in the disease being treated, that is sensitive and reproducible
• Composite endpoints are gaining increasing use as they incorporate multiple
domains of disease progression, enabling more events captured in a shorter period.
But which ones to include that are realistic and achievable is open to debate
• The recent introduction of a single phase 3 endpoint for improvement
in physical activity using accelerometry has been gaining acceptance.
Experience with both the composite or single (old or new) will be discussed
2.30 | 11.30
Exploring Endpoints in the Context of Inflammatory ILDs:
Debating Which Factors You Must Measure to Accurately Assess
the Efficacy of Treatment in Inflammatory vs Fibrotic ILDs
• Learning how to distinguish which endpoints to use for fibrotic vs
inflammatory ILDs
• How to effectively utilize endpoints to measure treatment efficacy in
interstitial lung disease
• Exploring challenges associated with utilizing endpoints for ILDs in 2022
and beyond
3.00 | 12.00
Afternoon Break & Networking
4.00 | 1.00
Machine Learning & Interstitial Lung Disease: A Deep Dive
• Understanding how machine learning can be utilized to inform respiratory
drug development
• Exploring computer-aided image analysis, machine learning and computer
vision for interstitial lung disease
• Looking into the crystal ball: Uncovering the future of imaging for ILDs
PARTNER WITH US
Innovative Imaging for Interstitial Lung Disease
Simon Walsh
Consultant
Thoracic
Radiologist,
Machine Learning
Scientist &
Imaging Chair
Imperial College
London
AGENDA
Elizabeth
Renzoni
Consultant
Respiratory
Physician,
Honorary Senior
Lecturer
Imperial College
London
Devising & Developing Composite Endpoints Which are Realistic &
Achievable to Use in Your Next Clinical Trial
SPEAKERS
Exploring Endpoints for Clinical Trials
Discovering Lumping vs Splitting Through a Wider Lens
4.30 | 1.30
• Understanding the difference between targeted therapies and more
broadly antifibrotic approaches
• How to evolve biomarkers in applying splitting strategies
• Lumping as a means to speed up patient recruitment
5.00 | 2.00
9
+1 617 455 4188
@
End of Conference Day One
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
Martin Kolb
Professor
McMaster
University
Scrutinizing the Practicalities of Deciding When to Lump or Split in
the Context of Disease Progression in Order to Inform & Optimize
Your ILD Drug Development Strategy
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
8.30 - 5.30 EDT | 5.30 - 2.30 PDT
WELCOME
Conference Day Two
Wednesday, March 9
Uncovering the Clinical Research Propelling ILD Drug Development Forwards in 2022 & Beyond
Registration & Networking
8.55 | 5.55
Chair’s Opening Remarks
9.00 | 6.00
Strategically Leveraging ILD Clinical Trials to Further Our
Understanding of The Progressive Pulmonary Fibrosis
Phenotype & Identify Novel Outcomes in Clinical Trials
Craig Conoscenti
Medical Expert ILD
Respiratory Clinical
Development &
Medical Affairs
Boehringer
Ingelheim
• Looking at previous clinical studies to understand primary, secondary
and exploratory outcomes and how these may help to better
characterize the progressive phenotype
• Looking at response rates of differing ILD diagnosis’ within previous
clinical trials in patients with the progressive phenotype
• Investigating previous exploratory/new composite outcomes and
understanding how to use them in new clinical trails given the existing
standard of care
9.30 | 6.30
Looking Beyond IPF: Utilizing Lessons Learned from IPF Clinical
Trials to Inform & Optimize Your ILD Trial Design & Execution
• Discussing the applicability of extrapolating data from IPF to other
disease
• Defining which ILD states are most believable to lump together with IPF
• Evaluating criteria used to lump and split, spotlight on CT imaging,
clinical characteristics, lung limited disease and more
10.00 | 7.00
Majd Mouded
Executive Director
Novartis
Uncovering Trial Design Considerations in Sarcoid
• Investigating the complexities of Sarcoid trial design
• Examining CMK-389 in sarcoid
• Gaining a high level overview of clinical trial design and execution
10.30 | 7.30
Speed Networking
11.00 | 8.00
Morning Break & Networking
AGENDA
Eric White
Senior Clinical
Program Lead
Boehringer
Ingelheim
SPEAKERS
8.30 | 5.30
Uncovering Emerging ILD Therapeutic Approaches
Vanessa Neins
Senior Scientist
- Biology Lead
Respiratory
Pieris
Pharmaceuticals
10
+1 617 455 4188
12.00 | 9.00
Lunch Break & Networking
1.00 | 10.00
Single vs Multiple Benefit Drugs for ILD
• Is it better to have a single target with multiple benefits?
• Investigating GSNOR inhibition
• Exploring single targets with no known safety issues
1.30 | 10.30
Update on Inhaled Drug Delivery: The Application of Anticalins
in the Treatment of Lung Fibrosis
• Highlighting the benefits of local intervention via inhalation versus
systemic administration
• Inhaled Anticalin antagonists for respiratory disease
• Reviewing the development of PRS-220, a potential best-in-class,
inhaled CTGF inhibitor for the treatment of IPF
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
Matt Bradley
Founder, Chairman,
President, and Chief
Technical Officer
SAJE Pharma
Developing Therapies for Rare Lung Diseases: ILD 101
• Discovering VP01 (C21) for interstitial lung disease
• Outlining our therapeutic approach for interstitial lung disease – how we
strategized our ILD drug development
• Exploring challenges associated with ILD drug development and
learning how to overcome them
PARTNER WITH US
11.30 | 8.30
Rohit Batta
Chief Scientific
Officer
Vicore Pharma
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
8.30 - 5.30 EDT | 5.30 - 2.30 PDT
WELCOME
Conference Day Two
Wednesday, March 9
Analyzing & Scrutinizing ILD Mechanisms
2.00 | 11.00
Evolution of Multicellular Hubs in the Tumor Microenvironment &
their Relevance for ILD Drug Development
• Investigating fibroblasts as drivers of fibrotic indications for lung diseases
• Exploring tools/pharmacologic agents to target fibrotic pathways/
inflammatory pathways
• Understanding the similarities and differences between cellular interactions
and molecular pathways in cancer and ILDs
2.30 | 11.30
The Role of Macrophage Metabolic Reprogramming During
Pulmonary Fibrosis
• Macrophages play a key role in the pathogenesis of IPF, but the role of
macrophage metabolism is not well understood.
• We have found that macrophages in IPF are metabolically reprogrammed with
alterations in iron (Allden et al, AJRCCM 2019), glycolysis (McErlean et al, AJRCCM
20201) and TCA cycle (Ogger et al, Science immunology 2020) pathways
• Macrophage metabolism therefore represents an exciting therapeutic target in IPF
Adam Byrne
Professor
Imperial College
London
3.00 | 12.00
Afternoon Break & Networking
Nicolas Guisot
Research Fellow
& Project Leader
Redx Pharma
Selective Inhibition of ROCK2: Promising Approach to Target
Fibrosis
• Understand the rationale for ROCK2 in lung fibrosis
• Assess the development of RXC007, a highly selective ROCK2 inhibitor
• Review preclinical studies in rodents and in Human Precision Cut Lung Slices
(PCLS)
4.30 | 1.30
• Examine interactions between injury repair cascade and fibrosis in IPF/ILD
• Evaluate druggability of pathways which target lung epithelial injury, repair
and regeneration
• How to kickstart your ILD drug discovery program
5.00 | 2.00
Chair’s Closing Remarks
5.05 | 2.05
End of Conference Day Two
University of Oxford
11
+1 617 455 4188
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
Excellent panel of speakers, thought
provoking discussions
PARTNER WITH US
Glenn Rosen
Chief Scientific
Officer
Optikira &
Biomotiv
Revealing What Steps You Must Take to Successfully Identify
& Validate Novel ILD Therapeutic Targets which Target Lung
Epithelial injury
AGENDA
Strategizing New Target Identification for Novel Therapies 101
4.00 | 1.00
SPEAKERS
Shannon Turley
Vice President
of Cancer
Immunology
Discovery
Genentech
An Interactive Online
Experience
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs
March 7-9, 2022 | Digital
WELCOME
The Digital 2nd ILD Summit will provide industry’s best opportunity for knowledge exchange and
networking to ensure you don’t miss out on timely scientific insights, data, and key lessons learned whilst
variants and vaccines remain a concern. Join your peers on our evolving and improving platform, and
immerse yourself in the industry’s most comprehensive ILD drug development conference without the
risk of having to isolate in the spring!
SPEAKERS
Our virtual platform has been upgraded for 2022 and has been specifically tailored to facilitate
personal online interactions and streamlined content to support ILD drug sponsors from target
identification through to regulatory approval, so you can make strategic decisions, overcome critical
challenges and accelerate pipeline success
Key Features & Functionalities:
Delegate Profile
Set up personalized
profiles to easily identify
the name, job title and company
of other attendees
Sessions Area
Most presentations
will be delivered in the
‘Stage’ area, much like the main
conference room onsite
Smaller groups can get
together in this breakout
area for panel discussions and
other interactive sessions
Chat Rooms
Visit the virtual
exhibition area
to explore the solutions our
specialist vendors have on offer
Connect with your peers
and start conversations
with individuals or all attendees
in private and public chatrooms
Speed Networking
This virtual networking
session will connect
you with other attendees to
establish new industry contacts
AGENDA
Demo Area
Stage Area
What You Can Expect from a Digital Event:
2+ Hours of Networking
Join smaller, informal
group chats or video
calls designed to spark
crucial conversations
around key challenges
for the industry
Facilitated and
informal networking
breaks will allow you
to connect 1-2-1 with
other attendees and
kick start critical
discussions
Content Available
Post-Event
On conclusion of the
event, presentations
will be made available
to attendees where
possible
If you have any other questions about the platform, please get in touch via info@hansonwade.com
12
+1 617 455 4188
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
Ask your burning
questions directly to
our expert speakers in
real-time, just as you
would at a physical
conference
Audience Discussions
PARTNER WITH US
Live Q&As with
Speakers
Why Partner?
March 7-9, 2022 | Digital
WELCOME
Proud to Partner With:
The trailblazing 2nd ILD Summit is no doubt your best opportunity to meet and develop lasting relationships with organizations
specifically seeking solutions in developing therapies against inflammatory and fibrotic interstitial lung disease.
We understand every business is different and have the expertise to create a bespoke package to align with your
commercial strategy. Get in touch today learn more about our exclusive partnership opportunities to accelerate the
process of establishing your business as thought leaders and foster long-term partnerships with fast growing ILD drug
development companies today!
Attending Seniority Breakdown from
ILD Summit from 2021
5%
25%
5%
C-level
Attending Companies Breakdown from
ILD Summit from 2021
20%
Executive Vice
President
Pharma &
Biotech
Senior Director
Academics
Head / Project
Team Leader
30%
15%
80%
Principal
/ Senior
Scientist
AGENDA
15%
SPEAKERS
Capitalize on our audience of highly engaged pulmonary fibrosis experts and proudly showcase your company, your brand,
and your services in front of the largest gathering of senior decision makers in the ILD drug development space this year.
Professor
*Based ILD Summit from 2021
*Based ILD Summit from 2021
Hanson Wade did a phenomenal job! Definitely the most productive conference so far this
year regarding the number of leads and quality of networking opportunities
PARTNER WITH US
Snapshot of Attending Companies in the Fibrosis Event Series
Vitalograph, IPF Summit Partner
13
+1 617 455 4188
@
info@hansonwade.com
www.ild-summit.com
REGISTER YOUR PLACE
Interested in
becoming a partner?
Nicholas Ramovic
Senior Partnerships Manager - Fibrosis
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com
Ready to Register?
www.ild-summit.com/take-part/register
Tel: +1 617 455 4188
Email: register@hansonwade.com
Conference Only
Service Provider Pricing
Conference Only
Academic Pricing
Conference & Investigating Inhaled Drug
Delivery Day
Conference & Exploring Biomarkers for
ILD Clinical Trials Workshop
On the Door Price
$2,647 (save $300)
$2,947
$2,398 (save $300)
$2,698
$1,799 (save $300)
$2,099
Register & Pay By
Friday, January 14
On the Door Price
$3,097 (save $400)
$3,497
$2,828 (save $400)
$3,228
$2,199 (save $400)
$2,599
Register & Pay By
Friday, January 14
On the Door Price
$2,097 (save $300)
$2,397
$1,888 (save $300)
$2,188
$1,399 (save $300)
$1,699
* Please note: If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a
reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.
*You must currently be developing drug candidate/s publicly (evidence on company website required).
** Reduced rates are available for full-time academics and startups (established for 5 years or less) and are subject to the organizer’s
approval, please get in touch at info@hansonwade.com for more information.
Team Discounts*
To qualify for group discounts, all passes must be purchased at the
same time. Group discounts will automatically be applied at checkout
if registering online. A customer service representative will be in touch
within one working day to confirm your registration.
Email info@hansonwade.com for more information on eligibility criteria.
T&Cs apply.
TERMS & CONDITIONS
Full payment is due on registration. Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received
more than 14 days before the conference attendees will receive a full credit
to a future conference. Cancellations received 14 days or less (including
the fourteenth day) prior to the conference will be liable for the full fee. A
substitution from the same organization can be made at any time.
14
+1 617 455 4188
@
Changes to Conference & Agenda: Every reasonable effort will be made to
adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or
location of the event. We reserve the right to amend or cancel any event at
any time. Hanson Wade is not responsible for any loss or damage or costs
incurred as a result of substitution, alteration, postponement or cancellation
of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident,
trade or industrial disputes, terrorism or hostilities.tage, accident, trade or
industrial disputes, terrorism or hostilities.
info@hansonwade.com
www.ild-summit.com
Data Protection: The personal information shown and/or provided by you
will be held in a database. It may be used to keep you up to date with
developments in your industry. Sometimes your details may be obtained or
made available to third parties for marketing purposes. If you do not wish
your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH
REGISTER YOUR PLACE
• 10% discount – 3 Attendees
• 15% discount – 4 Attendees
• 20% discount – 5 or more
Attendees
PARTNER WITH US
Conference Only
Register & Pay By
Friday, January 14
AGENDA
Conference & Investigating Inhaled Drug
Delivery Day
Conference & Exploring Biomarkers for
ILD Clinical Trials Workshop
Compare and contrast fibrotic and
inflammatory ILDs in order to comprehensively
understand key differences in their
development and progression, and learn how
this influences drug development
SPEAKERS
Conference & Investigating Inhaled Drug
Delivery Day
Conference & Exploring Biomarkers for
ILD Clinical Trials Workshop
Uncover anticalins, GSNOR’s and other
emerging therapeutics to inspire and revive
your therapeutic approach to treat ILD more
successfully
Learn how to use biomarkers to distinguish
patients with fibrotic vs inflammatory ILD in
order to strategically stratify trial populations
and maximize trial efficiency
Secure Your Place Now
Drug Developer Pricing
March 7-9, 2022 | Digital
WELCOME
3 Easy Ways To Book
Advancing Therapies for Inflammatory & Progressive Fibrosing ILDs